98%
921
2 minutes
20
In 2018, the Navi Mumbai Municipal Corporation implemented phase 1 of a public sector typhoid conjugate vaccine campaign in Navi Mumbai, India, targeting all children aged 9 months to 14 years within its administrative boundaries. To assess associations with receipt of vaccine in phase 1, we used generalized estimating equations to calculate estimates of vaccination by child-, household-, and community-level demographics (child education and age; household head education, income, and occupation; community informal settlement percent). Campaign vaccine receipt was most associated with children enrolled in school (odds ratio [OR] = 3.84, 95% CI: 2.18-6.77), the lowest household income tertile when divided into three equal parts (OR = 1.64, 95% CI: 1.43-1.84), and lower community-level socioeconomic status (OR = 1.06, 95% CI: 1.04-1.08 per 10% informal settlement proportion). The campaign was successful in reaching the most underserved populations of its target communities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542534 | PMC |
http://dx.doi.org/10.4269/ajtmh.24-0182 | DOI Listing |
Int J Exerc Sci
September 2025
Department of Musculoskeletal Physiotherapy, MGM School of Physiotherapy, MGM Institute of Health Sciences, Navi Mumbai, Maharashtra, India.
Osteoarthritis (OA) is a highly prevalent musculoskeletal condition. It is reported that knee OA progressively affects lower-extremity functioning. Evidence is lacking on when there is a substantial decline in function and whether this trend differs between males and females and disease severity.
View Article and Find Full Text PDFJ Ayurveda Integr Med
September 2025
Kode Lab, Tumor Immunology & Immunotherapy (TII) Group; Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, 410210, India; Anti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research and Education in Cancer (AC
Background: S. guineense DC. var.
View Article and Find Full Text PDFAcad Radiol
September 2025
Department of Radiology, New York University Langone Health, New York, NY (C.C.).
Medical imaging plays an increasingly central role in the diagnostic workup and management of patients. As imaging technologies evolve, the radiology community faces the challenge of balancing the diagnostic benefits of medical imaging with the potential risks associated with ionizing radiation. As part of the Association of Academic Radiology's 2025 Radiology Research Alliance task force, we present an updated review of the current literature on the risks associated with ionizing radiation in medical imaging, discuss technological advances focused on dose reduction, and present best practices for safety protocols.
View Article and Find Full Text PDFOrphanet J Rare Dis
September 2025
FRIGE's Institute of Human Genetics, FRIGE House, Jodhpur Gam Road, Satellite, Ahmedabad, 380015, India.
Background: Rare genetic disorders are increasingly diagnosed due to advancing genetic technology, whilst, treatment for them is challenging. Therefore, their prevention by prenatal diagnosis is a way forward to reduce the overall burden. The present study provides an overview of a cohort of patients who were offered prenatal diagnosis for genetic disorders at a tertiary genetic center in India.
View Article and Find Full Text PDFCureus
July 2025
Real-World Evidence, HealthPlix Technologies, Bengaluru, IND.
Background Metabolic disorders, including diabetes mellitus (DM), diabetic dyslipidemia (DD), and metabolic-dysfunction-associated steatotic liver disease (MASLD), are significant health challenges in India. This study aims to evaluate the real-world effectiveness and tolerability of saroglitazar (4mg) in Indian adults with type 2 diabetes mellitus (T2DM), DD, and MASLD, focusing on changes in glycemic, lipid, and hepatic biomarkers. Methods This retrospective study included adult patients with metabolic diseases (≥ 18 years) who were prescribed saroglitazar (4 mg) at baseline and continued therapy at least till the next follow-up visit after 90 days.
View Article and Find Full Text PDF